Home
Resources
Publications
Boron in Drug Design: Recent Advances in the Development of New Therapeutic Agents

Boron in Drug Design: Recent Advances in the Development of New Therapeutic Agents

Guilherme Felipe Santos Fernandes, William Alexander Denny, Jean Leandro Dos Santos

Eur J Med Chem. 2019 Oct 1;179:791-804.

PMID: 31288128

Abstract:

Advances in the field of boron chemistry have expanded the application of this element in Medicinal Chemistry. Boron-containing compounds represent a new class for medicinal chemists to use in their drug designs. Bortezomib (Velcade®), a dipeptide boronic acid approved by the FDA in 2003 for treatment of multiple myeloma, paved the way for the discovery of new boron-containing compounds. After its approval, two other boron-containing compounds have been approved, tavaborole (Kerydin®) for the treatment of onychomicosis and crisaborole (Eucrisa®) for the treatment of mild to moderate atopic dermatitis. A number of boron-containing compounds have been described and evaluated for a plethora of therapeutic applications. The present review is intended to highlight the recent advances related to boron-containing compounds and their therapeutic applications. Here, we focused only in those most biologically active compounds with proven in vitro and/or in vivo efficacy in the therapeutic area published in the last years.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP7440428	Boron		7440-42-8	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: